New markets for cancer drugs, including generic and biosimilar oncology medicines, can be created in low- and lower-middle income countries (LLMICs) by bringing together a broad network of partners to boost access and build market infrastructure, the Access to Oncology Medicines (ATOM) Coalition believes.
Led by the Union for International Cancer Control, the new coalition describes itself as “an innovative partnership of nearly 40...




